

**Cell Surface-based Sensing with Metallic Nanoparticles**

Journal:	<i>Chemical Society Reviews</i>
Manuscript ID:	CS-TRV-11-2014-000387.R2
Article Type:	Tutorial Review
Date Submitted by the Author:	18-Mar-2015
Complete List of Authors:	Jiang, Ziwen; University of Massachusetts--Amherst, Chemistry Le, Ngoc; University of Massachusetts--Amherst, Chemistry Gupta, Akash; University of Massachusetts--Amherst, Chemistry Rotello, Vincent M; University of Massachusetts at Amherst, Dept. of Chemistry (710A LGRT)

1                                    **Cell Surface-based Sensing with Metallic Nanoparticles**

2                                    **Ziwen Jiang, Ngoc D. B. Le,<sup>†</sup> Akash Gupta,<sup>†</sup> Vincent M. Rotello\***

3    Department of Chemistry, University of Massachusetts Amherst, 710 North Pleasant St, Amherst,  
4    Massachusetts, MA 01003, USA

5    <sup>†</sup> These authors equally contributed to this work.

6

7    \* Correspondence should be addressed to Vincent M. Rotello (V. M. R.).

8    **Address:**

9    Department of Chemistry

10    710 North Pleasant Street

11    University of Massachusetts

12    Amherst, MA 01003, USA.

13    **Tel.:** +1 413 545 2058; **fax:** +1 413 545 4490.

14    **E-mail:** [rotello@chem.umass.edu](mailto:rotello@chem.umass.edu).

15

## 16 Abstract

17 Metallic nanoparticles provide versatile scaffolds for biosensing applications. In this  
18 review, we focus on the use of metallic nanoparticles for cell surface sensings. Examples of the  
19 use of both specific recognition and array-based “chemical nose” approaches to cell surface  
20 sensing will be discussed.

21

## 22 Key learning points

23 1. Both cell surface biomarkers (such as carbohydrates and proteins) and the overall cell surface  
24 signatures provide crucial information for identifying cell types.

25 2. Metallic nanoparticles provide multiple modes of signal transduction for biosensing  
26 applications.


27 3. Surface functionalization determines how nanoparticles interact with cell surfaces.

28 4. The specific recognition capabilities of biomacromolecules such as antibodies, lectins,  
29 aptamers, and DNAzymes can be coupled with nanoparticle transduction processes to design cell  
30 sensing strategies.

31 5. Nanoparticle surface can be functionalized with a variety of small molecule ligands to provide  
32 the selective recognition required for array-based sensing.

33

## 34 TOC



35

36

## 37 **1. Introduction**

38 Cell surface sensors for disease and detection of infection have direct access to the  
39 sensing target, in contrast to approaches that detect intracellular proteins, nucleic acids, or other  
40 markers buried inside the cells. This ready access has the potential to provide rapid sensing with  
41 minimal processing. The rich environment presented by the cell exterior also gives cell surface  
42 sensors the capability to read out the phenotypes of cells, a property that is the final outcome of  
43 multiple factors including both genetic and epigenetic variations.<sup>1</sup> For example, in the case of  
44 cancer, abnormal cells have been found to overexpress specific glycosylated proteins at their  
45 plasma membrane such as epithelial cell adhesion molecule (EpCAM) or carcinoembryonic  
46 antigen (CEA).<sup>2-4</sup> Therefore, targeting cell surface phenotype provides a strategy for simple,  
47 rapid, and robust diagnostic pathways in diverse areas such as cancer and pathogenic bacteria.

48  
49 Three integrated components are necessary to fabricate an effective sensor: (1) a  
50 recognition element to interact with a target analyte, (2) a signal transduction element to generate  
51 a measurable signal from an analyte-receptor binding event, and (3) a device that outputs a result.  
52 Metallic nanoparticles (NPs) can be easily engineered to provide scaffolds for recognition  
53 processes, with their physical properties facilitating the transduction process, making them  
54 excellent platforms for cell surface sensing.<sup>5,6</sup>

55  
56 In this review, we will focus on the use of metallic NPs for the detection and  
57 quantification of cell properties, based on cell surface components. We will discuss examples of  
58 different engineered metallic NP systems<sup>7,8</sup> that provide cell sensing through specific and  
59 selective interactions with the cell surfaces.

60

## 61 **2. Cell surface and nanoparticle interactions**

62 Enormous cell surface diversity exists among cells from plants, bacteria, and animals.  
63 The surface of a mammalian cell is composed of a complex structure featuring the lipid bilayer,  
64 proteins, nucleic acids as well as a range of polysaccharide structures that comprise the  
65 glycocalyx.<sup>9</sup> This glycocalyx is composed of glycoproteins, proteoglycans and glycolipids.<sup>10</sup>  
66 Phenotypically altered expression of each of these components provides diagnostic information  
67 for diseases such as cancer, Gaucher's, and Tay-Sachs diseases.<sup>11,12</sup> Taken together, the complex

68 array of biomolecules that comprise cell surfaces make them excellent targets for both specific  
69 biomarker sensing and selective “chemical nose” based methods.

70  
71 The interaction between nanomaterials and cells is an important issue for designing  
72 systems not only for sensing, but also for imaging and delivery. In general, the following factors  
73 need to be taken into account: (1) specific receptors (biomarkers) on the cell membrane, (2) the  
74 size, shape, surface charge, roughness and hydrophobicity of nanoparticles and their role in  
75 selective interactions. While these topics are all central to the sensing described here, the in-  
76 depth discussion required for understanding this interaction is beyond the scope of this tutorial  
77 discussion. Nel and coworkers have provided a comprehensive review to help understand the  
78 biophysicochemical interactions at the nano-bio interface, which discussed cell-nanoparticle  
79 interactions in detail.<sup>13</sup>

80

### 81 **3. Specific sensing**

82 We will focus on spherical metallic nanoparticles in this review, as these systems have  
83 been widely employed for cell surface sensing. Metallic nanoparticles can be functionalized with  
84 small molecules<sup>14</sup> and biomacromolecules<sup>15</sup> to achieve the specific interactions with the  
85 biological targets. However, the vast majority of specific-based sensors have been using  
86 biomacromolecules to functionalize metallic nanoparticles, so we will focus on these  
87 bioconjugate systems. These platforms provide highly adaptable tools for rapid and/or point-of-  
88 care tools that provide alternatives to more complex and instrument-intensive techniques such as  
89 flow cytometry.<sup>16</sup>


90

#### 91 **3.1. Antibody-based sensing**

92 Antibodies are widely used as recognition elements in diagnostic and therapeutic  
93 applications.<sup>17</sup> There are two key components of antibodies: the Fab (fragment, antigen-binding)  
94 region of an antibody that recognizes the antigen and the Fc (fragment, constant) that can be used  
95 for conjugation without disrupting the recognition process. Conjugation of either complete  
96 antibodies or Fab fragments to NPs provides an effective means of recognizing cell surface  
97 functionality. As described below, these binding events can be detected *via* various tools such as  
98 surface-enhanced Raman scattering (SERS) and electrochemistry.

99

100 SERS is a technique in which the Raman signal can be dramatically amplified through  
101 surface plasmon resonance of metallic NPs.<sup>6</sup> SERS-based techniques utilizing antibodies have  
102 been successfully applied to immunoassay-based methodologies.<sup>18</sup> In one example, Sha and  
103 coworkers detected cancer circulating cells (CTCs) by combining capturing capability of a  
104 magnetic bead and specific labeling of SERS nanotags.<sup>19</sup> This bead was conjugated with anti-  
105 EpCAM antibody to capture SKBR3 cancer cells. These cells were then labeled for SERS  
106 detection by AuNPs functionalized with anti-HER2 antibody (human epidermal growth factor  
107 receptor-2). A silica shell was subsequently coated on this complex to enable the  
108 functionalization of antibody on the particle without interfering with the Raman response (Figure  
109 1). In a similar study, SERS-based systems were further employed for *in vivo* tumor targeting.  
110 Poly(ethylene glycol)-capped AuNPs were used to stabilize Raman-active reporter molecules.  
111 The SERS-NPs were conjugated with antibodies specifically targeting the overexpressed  
112 epidermal growth factor receptor on tumor cells, resulting in highly specific *in vivo* tumor  
113 detection.<sup>20</sup>



114


115 **Figure 1** Tumor cell detection using anti-HER2 antibody-conjugated magnetic beads with SERS  
116 nanotags. Reprinted with permission from ref. 19. Copyright 2008 American Chemical Society.

117

118 Electrochemical detection technique can utilize the electrocatalytic properties of AuNPs  
119 to provide rapid cell surface sensing.<sup>21</sup> This strategy has the advantages of simpler

120 instrumentation coupled with the direct connection of sensor output with devices/computers. For  
121 example, Merkoçi and coworkers employed antibody-conjugated magnetic beads and AuNPs for  
122 the detection of CTC (Figure 2).<sup>22</sup> AuNPs fabricated with anti-EpCAM antibody were used for  
123 targeting EpCAM, an overexpressed transmembrane glycoprotein on human colon  
124 adenocarcinoma cells (Caco2 cells). The AuNP-antibody conjugates were used to generate an  
125 electrochemical signal through electrocatalytic hydrogen evolution. The signals generated from  
126 AuNP-antibody conjugates could detect  $2.2 \times 10^2$  Caco2 cells in the presence of other interfering  
127 cells such as monocytes (THP-1).

128



129

130 **Figure 2** (a) Capture of Caco2 cells by magnetic beads conjugated to anti-EpCAM.  
131 Simultaneously, cells were labeled with AuNP-specific antibodies in the presence of interfering  
132 cells (THP-1). (b) Chronoamperometry of the hydrogen evolution reaction (HER)  
133 electrocatalyzed by AuNPs. (c), (d) False colors scanning electron microscopy (SEM) images of  
134 a Caco2 cell captured by magnetic beads (MBs)/anti-EpCAM. (e), (f) Backscattered images

135 showing AuNPs distributed along the cell plasma membrane of Caco2 cells. Scale bars, 3  $\mu\text{m}$  (c),  
136 400 nm (d), and 200 nm (e, f). Reprinted with permission from ref. 22. Copyright 2012  
137 American Chemical Society.

138

### 139 **3.2. Lectin-based sensing**

140 Lectins are proteins that exhibit strong and specific or selective binding towards  
141 carbohydrate moieties. Targeting carbohydrates has been the useful strategy for diagnosis  
142 because the alterations of carbohydrates found on plasma membrane have been correlated with  
143 disease, such as liver fibrosis, pancreatic cancer, and cervical cancers.<sup>23</sup> Thus, NPs  
144 functionalized with lectins can be a powerful tool for cell surface sensing.<sup>24</sup>


145

146 In a recent study, Liu and coworkers designed a sensitive electrochemiluminescence<sup>25</sup>  
147 (ECL)-based biosensor using a displacement assay that relies on the interaction between NP-  
148 bound lectins and carbohydrates on the cell surface (Figure 3).<sup>26</sup> In this system, a gold electrode  
149 immersed in luminol solution was coated with Concanavalin A (ConA), a lectin that recognizes  
150 mannose (a carbohydrate type found on the cell surface). These mannose moieties can also be  
151 found in glucose oxidase molecules (GOx), an enzyme that can catalyze the luminol ECL  
152 reaction. By coupling GOx with AuNPs (GOx-Au), they were able to fabricate a multifunctional  
153 probe. This GOx-Au probe can both compete with mannose moieties on the analyte cells for  
154 ConA-coated gold electrode and improve the ECL signal of luminol. In the presence of the target  
155 cells, the competition between GOx-Au and mannose-containing cells generates the alterations in  
156 ECL signal intensity, providing the ability to profile carbohydrate-lectin interaction and *in situ*  
157 cell surface carbohydrate expression.

158

159

160




161  
 162 **Figure 3** Schematic illustration of the lectin-based sensing strategy for (a) carbohydrate-ConA  
 163 interaction analysis and (b) cell surface carbohydrate expression. Reprinted with permission from  
 164 ref. 26. Copyright 2013 Royal Society of Chemistry.

165  
 166 **3.3. Aptamer-based sensing**  
 167 Short, single-stranded oligonucleotides (ssDNA or ssRNA), known as aptamers, provide  
 168 an emerging strategy for biorecognition. Aptamers are produced from an *in vitro* method known  
 169 as SELEX (systematic evolution of ligands by exponential enrichment). In this process, SELEX  
 170 uses polymerase chain reaction (PCR) to specifically amplify the sequence that has high affinity  
 171 and selectivity to the target analyte. The iterative process generates aptamers that often fold into  
 172 unique three-dimensional conformations. Aptamers can bind to target molecules ranging from  
 173 small organic molecules to biomacromolecules,<sup>27</sup> making them promising candidates to serve as  
 174 recognition elements in biosensors.


175  
 176 The recognition capabilities of aptamers can be combined with the spectroscopic  
 177 advantages of AuNPs for cell detection applications. AuNPs possess strong distance dependent  
 178 optical properties due to surface plasmon resonance.<sup>28</sup> The aggregation of aptamer-conjugated  
 179 AuNPs causes a shift in their absorption spectra, resulting in a change in their scattering profile  
 180 and color from red to blue/purple.<sup>29</sup> This colorimetric sensing method has been applied using  
 181 aptamers for the detection of cancer cells. For instance, Tan and coworkers successfully applied

182 the aggregation-based colorimetric sensing platform to detect cancer cells using AuNPs  
183 functionalized with the aptamers of interest.<sup>30</sup> The specific interaction between AuNP-aptamer  
184 conjugates and the target cells (CCRF-CEM acute leukemia cell) induced a distinct color change  
185 (Figure 4).




186  
187 **Figure 4** Aptamer-conjugated gold nanoparticles used in colorimetric sensing of cancer cells.

188  
189 Recently, DNA-templated silver nanoclusters (DNA-AgNCs) were used as a signal  
190 transduction element for use with aptamers. The fluorescence of DNA-AgNCs can be  
191 significantly amplified in proximity of guanine-rich DNA sequences,<sup>31</sup> a phenomena Wang and  
192 coworkers have applied in cell surface-based sensing.<sup>32</sup> They designed a “turn-on” system for  
193 cancer cell detection, utilizing the fluorescence enhancement of DNA-AgNCs and the  
194 recognition capability of aptamers. Two separate DNA-based probes were involved in this  
195 system, denoted as the recognition probe and signal probe. The recognition probe was designed  
196 as a hairpin-shaped structure that contains a CCRF-CEM cancer cell specific aptamer sequence,  
197 a guanine-rich DNA sequence and an arm segment. The signal probe contains a sequence for  
198 AgNC-templated synthesis and a link sequence that is complementary to the arm segment of the  
199 recognition probe. Once the aptamer sequence from the recognition probe recognizes and binds  
200 to CCRF-CEM cells, the recognition probe undergoes a conformational alteration. This  
201 conformational alternation then initiates the hybridization of the two probes and consequently  
202 brings DNA-AgNCs close to the guanine-rich DNA sequence, resulting in an enhanced  
203 fluorescence readout (Figure 5).



204  
205 **Figure 5** Schematic representation of cancer cell detection based on DNA-templated silver  
206 nanoclusters (AgNCs). Reprinted with permission from ref. 32. Copyright 2013 American  
207 Chemical Society.

208  
209 Aptamer-based specific sensing can also be used to detect different cancer cells using an  
210 electrochemical approach. By combining multiple metallic NPs with electrochemical analysis,  
211 Kelley and coworkers designed a chip-based strategy for the analysis of cancer cells associated  
212 with different tumor phenotypes.<sup>33</sup> Pd, Ag, and Cu NPs were chosen as signal reporters since  
213 they have well-separated potentials as redox-active probes. Biomarker-specific aptamers were  
214 conjugated with these three types of metallic NPs to form Pd-anti-PSMA, Ag-anti-HER2, and  
215 Cu-anti-MUC1 NPs. A mixture of these three NPs were successfully used for the specific  
216 detection of different prostate and breast cancer cell lines such as VCaP, SK-BR-3, and MDA-  
217 MB-231 (Figure 6).



218  
219 **Figure 6** Linear-sweep voltammetry of specific cancer cell detection with a mixture of Pd-anti-  
220 PSMA, Cu-anti-MUC1, and Ag-anti-HER2 nanoparticles: VCaP (blue), MDA-MB-231 (black)  
221 and SK-BR-3 (red) cells. Reprinted with permission from ref. 33. Copyright 2014 WILEY-VCH  
222 KGaA, Weinheim.

223

### 224 3.4. DNAzyme-based sensing

225 Deoxyribozymes, known as DNAzymes or catalytic DNAs, provide an alternative  
226 approach to biosensing. DNAzymes are selected from random DNA sequences through  
227 combinatorial screening techniques for catalytic and ligand-binding activities.<sup>34</sup> DNAzyme-  
228 based sensing relies on the optical property of AuNPs for target recognition role for analytes  
229 such as as metal ions and small organic molecules. Using such DNAzyme-functionalized AuNPs,  
230 the DNAzyme-catalyzed cleavage or ligation of the nucleic acid substrates affects the assembly  
231 of AuNPs, resulting in a colorimetric readout for the cofactors.<sup>34</sup>

232

233 DNAzymes can also be used for signal amplification by behaving as peroxidase mimics.  
234 For example, it has been found that when one certain DNA sequence binds with hemin,  
235 DNAzyme can be formed with G-quadruplex motifs. This type of DNAzyme can catalyze the  
236 generation and enhancement of chemiluminescence (CL) signals in the presence of luminol and  
237 H<sub>2</sub>O<sub>2</sub>. In this process, AuNPs are employed as carriers for these horseradish peroxidase (HRP)-  
238 mimicking DNAzymes.<sup>35</sup> In a recent study, Zhang and coworkers applied HRP-mimicking  
239 DNAzyme-functionalized NPs to cancer cell detection through the amplified CL signals.<sup>36</sup>

240


241 **4. Selective sensing**

242 Specific recognition-based sensors require pre-identification of the biomarkers, and face  
243 certain limitations when used in systems containing multiple analytes. For example, cancer cells  
244 present multiple biomarkers on the cell surface. The level of biomarkers may vary among cell  
245 populations. In addition, subtle changes in the biomarker levels may be indicative of dramatic  
246 phenotypic differences. As an alternative, sensors using *selectivity*-based modality do not require  
247 the knowledge of a specific biomarker. On the contrary, selectivity-based approaches capture the  
248 responses from complex analytes to generate a signature for each sample. Such selective sensing  
249 approach can be utilized to detect non-specific analytes with either a single recognition element  
250 or more commonly an array of recognition elements. In a typical array-based sensor, a set of  
251 recognition elements interacts with a number of different analytes or classes of analytes,  
252 providing a process reminiscent of mammalian olfaction.<sup>37</sup> This mechanistic similarity is why  
253 array-based sensors are often denoted as chemical “noses” or “tongues”.

254

255 **4.1. Single recognition element system**

256 Rotello and coworkers have developed an enzyme amplification sensor using cationic  
257 AuNP to inhibit the activity of  $\beta$ -galactosidase ( $\beta$ -gal) based on electrostatic interaction.<sup>38</sup> Such  
258 enzyme catalysis can amplify the weak signals generated by the system. Bacterial cell surfaces  
259 are negatively charged which can disrupt the AuNP- $\beta$ -gal conjugates. During the sensing process,  
260 bacteria cells replace  $\beta$ -gal from the NP- $\beta$ -gal conjugates, restoring the activity of  $\beta$ -gal towards  
261 the chromogenic substrate. Finally, the enzymatic reaction on the substrate gives the  
262 corresponding readout to quantify the analytes (Figure 7).<sup>39</sup> The enzyme-amplified colorimetric  
263 readout was able to detect  $10^2$  CFU/mL of *Escherichia coli* (*E. coli*) in solution. Furthermore, the  
264 performance of this methodology was tested on a paper strip format against concentrations of  
265 bacteria ranging from  $10^4$ ~ $10^8$  CFU/mL. The designed bacteria test strips demonstrate the  
266 potential for field applications such as a test of drinking water safety. However, this strategy  
267 displays limitations in sensitivity and multiple analyte detection capability due to insufficient  
268 interactions between the single recognition element and the analytes.



269  
 270 **Figure 7** (a) Schematic demonstration of enzyme amplified sensing of bacteria using gold  
 271 nanoparticles. (b) The structure of quaternary amine functionalized gold nanoparticles. (c) The  
 272 colorimetric sensing of *Escherichia coli* (*E. coli*) in solution. (d) Schematic illustration of the  
 273 RGB analysis for monitoring color changes on test strips for different concentrations of *E. coli*.  
 274 Reprinted with permission from ref. 39. Copyright 2011 American Chemical Society.

275

## 276 4.2. Array based sensing systems

277 Multiple recognition elements can maximize the variation in interactions between sensors  
 278 and analytes. This array-based strategy combines responses from many individual sensors and  
 279 analytes to generate a distinct pattern (fingerprint) for each analyte, either based on specific or  
 280 selective interactions. Since multiple responses can be obtained from array-based sensors, these  
 281 data matrices are generally analyzed using a variety of multivariate analyses such as principal  
 282 component analysis (PCA) or linear discriminant analysis (LDA).<sup>40</sup>

283


284 NPs can be readily functionalized with ligands to generate diverse sensor elements. These  
 285 head groups exhibit differential affinity towards various analytes, leading to variations in the  
 286 sensor that can be correlated to cellular signatures. Rotello and coworkers have designed several

287 small molecule based sensor arrays that used the phenomenon of fluorescence quenching.<sup>41</sup>  
288 Fluorescence quenching is reduction in the fluorescence quantum yield due to energy transfer  
289 from the photo-excited fluorophore to the AuNPs. In one approach, gold nanoparticles (AuNPs)  
290 with a fluorescent polymer [carboxylate poly(para-phenyleneethynylene) (PPE-CO<sub>2</sub>)] were used  
291 to discriminate a series of cell lines (Figure 8).<sup>42</sup> The sensor was comprised of three NP types  
292 with different quaternary amine functional head groups. An array of AuNPs was used to quench  
293 the intensity of the fluorescent polymers *via* electrostatic interaction. The subsequent binding of  
294 cells disrupted the AuNP-polymer complex, thereby generating different fluorescence response  
295 patterns for each cell lines. This AuNP-polymer complex was able to identify human cancerous  
296 (MCF-7), metastatic (MDA-MB231) and normal (MCF10A) breast cell lines. Since these cell  
297 lines came from different individuals, their differentiation might be originating from genetic  
298 variation. To avoid this possibility, isogenic cell lines [CDBgeo (normal), TD (cancerous) and  
299 V14 (metastatic)] derived from BALB/c mice were used to validate the sensor. Fluorescent  
300 proteins can also be used as a transducer in an array based sensor. Cell differentiation using  
301 AuNP-green fluorescent protein (GFP) conjugates resulted in four-fold enhancement in the  
302 sensitivity of “chemical nose”-based sensor.<sup>43</sup> Moreover, in a subsequent study, AuNP-GFP  
303 constructs were used to discriminate site specific metastases and healthy state using cell lysates  
304 as well as tissue lysates, providing a promising strategy for medical diagnosis.<sup>44</sup>

305

306

307



308

309 **Figure 8** (a) Cationic gold nanoparticles (NP1-NP3) and the fluorescent polymer, carboxylate  
 310 poly(para-phenyleneethynylene) (PPE-CO<sub>2</sub>). (b) Fluorescence quenching of the polymers and  
 311 the restoration of fluorescence after AuNP-polymer complex disrupted by the incubation with  
 312 cells (dark green strips, fluorescence off; light green strips, fluorescence on). (c) Detection of  
 313 three isogenic mammalian cell lines (CDBgeo, TD cell and V14) determined by fluorescence  
 314 change using nanoparticle-polymer supramolecular complexes. (d) Canonical score plot using  
 315 linear discrimination analysis (LDA) for the first two factors of simplified fluorescence response  
 316 patterns obtained with NP-polymer assembly arrays against isogenic cell types. Reprinted with  
 317 permission from ref. 42. Copyright 2009 National Academy of Sciences, USA.


318

319 In an analogous study, a swallowtail substituted carboxylate PPE (Sw-CO<sub>2</sub>) was used as a  
 320 transducer for AuNP-polymer sensor.<sup>45</sup> This array-based system comprised of amine  
 321 functionalized hydrophobic NPs that served as recognition units for microorganisms such as  
 322 bacteria. Bacterial cell walls are negatively charged and furnish a polyvalent environment to  
 323 interact selectively with AuNP-polymer complex. For example, the Gram-positive  
 324 microorganisms are highly negatively charged due to the presence of teichoic acid residue,  
 325 whereas *E. coli* bacteria possess pili (rich in lectins) emanating from the surface. This array-  
 326 based sensor enables the detection of bacteria cells within minutes. The AuNP-polymer complex  
 327 was disrupted *via* competitive binding of different bacteria strains with the AuNP. Twelve

328 different bacteria strains including Gram-positive strains such as *Bacillus subtilis*, *Amycolatopsis*  
329 *azurea* and Gram-negative bacteria such as *E. coli*, and *Pseudomonas putida* were identified.

330

331 Recently, quantum dots (QDs) were used in an array-based sensor as a recognition  
332 element alongside AuNPs. When added together to the cells, co-localization of AuNPs and QDs  
333 resulted in quenching, generating different patterns based on cell type/state. This sensor was used  
334 to differentiate four different types of cancer cells as well as isogenic normal, cancer and  
335 metastatic cells (Figure 9).<sup>46</sup> The dual channel fluorescence response obtained from the QD-  
336 AuNP sensor array could identify 30 unknown samples with 100% accuracy. Besides pairing  
337 with QDs, AuNPs can also be combined with upconversion nanoparticles (UCNPs) as a  
338 fluorescence resonance energy transfer (FRET) couple to design biosensors.<sup>47</sup>



339  
 340 **Figure 9** (a) Schematic illustration of the interaction between the nanoparticles and cell surface.  
 341 The sensing system generated differential quenching and provided distinct patterns to discern  
 342 different types/states of cells. Two arrays ( $|QD|_M$  and  $|QD/AuNP|_M$ ) were used in the system and  
 343 placed in separated wells, with each array providing two fluorescence responses.  $|QD|_M$ , the  
 344 mixture of GQD and RQD;  $|QD/AuNP|_M$ , the mixture of GQD, RQD, and AuNP. (b)-(i)  
 345 Confocal microscopy images of (b)-(e)  $|QD|_M$  and (f)-(i)  $|QD/AuNP|_M$  after the incubation with  
 346 HeLa cells for 15 min: (b), (f) bright field; (c), (g) green channel; (d), (h) red channel; (e), (i)  
 347 merged images. Reprinted with permission from ref. 46. Copyright 2013 Elsevier.

348


349           Functionalization of biomolecules such as aptamers on NPs can also be used for selective  
350 identification of target analytes. Aptamers with selective binding properties towards were coated  
351 on citrate capped AuNPs.<sup>48</sup> Upon addition of the target cells, aptamer-protected AuNPs  
352 displayed different aggregation, generating different color patterns. Human cancer cells (Jurkat,  
353 Reh, Raji) and normal human cells (WIL2-S) were distinguished with the array-based approach  
354 by using one human immunoglobulin E aptamer (HIgE-1) and two thrombin aptamers (Tro-1  
355 and Tro-2).

356

### 357 **4.3. Multiplexed output sensing system**

358           The previous array-based sensing examples use separate recognition elements to generate  
359 the multiple sensor outputs required for identification of analytes. An alternative strategy to  
360 generating information-rich data would be to use a single recognition element with multiple  
361 outputs. Very recently, Rotello and coworkers have developed a high-throughput multi-channel  
362 sensor that classifies the mechanism of chemotherapeutic drugs in minutes.<sup>49</sup> This sensor  
363 consists of a single AuNP complexed with three different fluorescent proteins (FPs) that is used  
364 to sense drug-induced physicochemical changes on cell surfaces. In the presence of cells,  
365 differential displacement of the fluorophores with concomitant fluorogenesis provide a  
366 ratiometric output that is measurable from a single readout (Figure 10). This result demonstrates  
367 the ability of cell surface sensing to be used for high throughput screening of therapeutics, and  
368 suggests the utility of these sensors for applications in toxicology and related fields.

369



370  
 371 **Figure 10** Multi-channel sensor fabricated by incubating AuNP to an equimolar mixture of three  
 372 fluorescent proteins (FPs): tdTomato (red), EBFP2 (blue) and EGFP (green). Different drug-  
 373 treated cells result in distinct cell surface phenotypes, leading to different FP displacement  
 374 patterns as schematically shown for the three wells. The bar plot shows differential fluorescence  
 375 responses for three representative drugs. These fluorescence responses were further analyzed by  
 376 linear discriminant analysis (LDA) to generate different clusters corresponding to different  
 377 categories of drug mechanisms. Each ellipse represents each drug in that mechanism category.  
 378 Adapted with permission from ref. 49. Copyright 2014 by Nature Publishing Group.

379

## 380 5. Conclusions and prospects

381 Metallic NPs present a versatile platform for the creation of recognition elements for  
 382 analyzing the biological targets. NPs can be fabricated with different recognition elements to  
 383 provide specific or selective interactions with the target analytes. Moreover, physiochemical  
 384 properties of the NPs such as fluorescence quenching or enhancement, surface enhanced Raman  
 385 scattering and electrochemical activity can be harnessed to signal the transduction of the binding  
 386 events. Hence, inclusion of NPs can simplify the system design as well as increase the sensitivity  
 387 of the biosensors.

388

389 Incorporation of metallic nanoparticles in diagnostic techniques has opened promising  
 390 avenues for a wide range of sensing strategies that feature combinations of simplicity, rapid

391 output, low cost platforms and multiplexing. As we develop better strategies for particle  
392 functionalization and signal transduction, a wide range of platforms ranging from microfluidic  
393 sensors through inexpensive paper test strips will be enabled, provide solutions to address health  
394 issues worldwide.

395

### 396 **Acknowledgment**

397 The authors declare no competing financial interest. The authors thank Rubul Mout (University  
398 of Massachusetts--Amherst) and Rui Tang (University of Massachusetts--Amherst) for their help  
399 in preparing the manuscript. This work was supported by The NIH (GM077173) and the NSF  
400 (Center for Hierarchical Manufacturing, CMMI-1025020).

401

### 402 **References**

- 
- 1 H. Shen and P. W. Laird, *Cell*, 2013, **153**, 38-55.
  - 2 M. Ferrari, *Nat. Rev. Cancer*, 2005, **5**, 161-171.
  - 3 L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes and R. C. Bast, Jr., *J. Clin. Oncol.*, 2007, **25**, 5287-5312.
  - 4 M. Trzpis, P. M. J. McLaughlin, L. M. F. H. de Leij and M. C. Harmsen, *Am. J. Pathol.*, 2007, **171**, 386-395.
  - 5 P. K. Jain, X. H. Huang, I. H. El-Sayed and M. A. El-Sayed, *Acc. Chem. Res.*, 2008, **41**, 1578-1586.
  - 6 R. A. Sperling, P. Rivera Gil, F. Zhang, M. Zanella and W. J. Parak, *Chem. Soc. Rev.*, 2008, **37**, 1896-1908.
  - 7 E. Katz and I. Willner, *Angew. Chem. Int. Ed.*, 2004, **43**, 6042-6108.
  - 8 R. Mout, D. F. Moyano, S. Rana and V. M. Rotello, *Chem. Soc. Rev.*, 2012, **41**, 2539-2544.
  - 9 M. Edidin, *Nat. Rev. Mol. Cell Biol.*, 2003, **4**, 414-418.
  - 10 M. D. Mager, V. LaPointe and M. M. Stevens, *Nat. Chem.*, 2011, **3**, 582-589.
  - 11 D. H. Dube and C. R. Bertozzi, *Nat. Rev. Drug Discov.*, 2005, **4**, 477-488.
  - 12 K. Ohtsubo and J. D. Marth, *Cell*, 2006, **126**, 855-867.
  - 13 A. E. Nel, L. Maedler, D. Velegol, T. Xia, E. M. V. Hoek, P. Somasundaran, F. Klaessig, V. Castranova and M. Thompson, *Nat. Mater.*, 2009, **8**, 543-557.
  - 14 J. Sudimack and R. J. Lee, *Adv. Drug Del. Rev.*, 2000, **41**, 147-162.
  - 15 N. L. Rosi and C. A. Mirkin, *Chem. Rev.*, 2005, **105**, 1547-1562.
  - 16 N. Rifai, M. A. Gillette and S. A. Carr, *Nat. Biotechnol.*, 2006, **24**, 971-983.
  - 17 P. Holliger and P. J. Hudson, *Nat. Biotechnol.*, 2005, **23**, 1126-1136.
  - 18 M. D. Porter, R. J. Lipert, L. M. Siperko, G. Wang and R. Narayanan, *Chem. Soc. Rev.*, 2008, **37**, 1001-1011.
  - 19 M. Y. Sha, H. Xu, M. J. Natan and R. Cromer, *J. Am. Chem. Soc.*, 2008, **130**, 17214-17215.

- 
- 20 X. Qian, X.-H. Peng, D. O. Ansari, Q. Yin-Goen, G. Z. Chen, D. M. Shin, L. Yang, A. N. Young, M. D. Wang and S. Nie, *Nat. Biotechnol.*, 2008, **26**, 83-90.
- 21 E. Katz, I. Willner and J. Wang, *Electroanalysis*, 2004, **16**, 19-44.
- 22 M. Maltez-da Costa, A. de la Escosura-Muniz, C. Nogues, L. Barrios, E. Ibanez and A. Merkoci, *Nano Lett.*, 2012, **12**, 4164-4171.
- 23 R. Jelinek and S. Kolusheva, *Chem. Rev.*, 2004, **104**, 5987-6016.
- 24 L. Ding, W. Cheng, X. Wang, S. Ding and H. Ju, *J. Am. Chem. Soc.*, 2008, **130**, 7224-7225.
- 25 L. Hu and G. Xu, *Chem. Soc. Rev.*, 2010, **39**, 3275-3304.
- 26 Y. Wang, Z. Chen, Y. Liu and J. Li, *Nanoscale*, 2013, **5**, 7349-7355.
- 27 X. Fang and W. Tan, *Acc. Chem. Res.*, 2010, **43**, 48-57.
- 28 S. Srivastava, B. L. Frankamp and V. M. Rotello, *Chem. Mater.*, 2005, **17**, 487-490.
- 29 J. Liu and Y. Lu, *Nat. Protoc.*, 2006, **1**, 246-252.
- 30 C. D. Medley, J. E. Smith, Z. Tang, Y. Wu, S. Bamrungsap and W. Tan, *Anal. Chem.*, 2008, **80**, 1067-1072.
- 31 H.-C. Yeh, J. Sharma, J. J. Han, J. S. Martinez and J. H. Werner, *Nano Lett.*, 2010, **10**, 3106-3110.
- 32 J. Yin, X. He, K. Wang, F. Xu, J. Shanguan, D. He and H. Shi, *Anal. Chem.*, 2013, **85**, 12011-12019.
- 33 Y. Wan, Y.-G. Zhou, M. Poudineh, T. S. Safaei, R. M. Mohamadi, E. H. Sargent and S. O. Kelley, *Angew. Chem. Int. Ed.*, 2014, **53**, 13145-13149.
- 34 J. Liu, Z. Cao and Y. Lu, *Chem. Rev.*, 2009, **109**, 1948-1998.
- 35 T. Niazov, V. Pavlov, Y. Xiao, R. Gill and I. Willner, *Nano Lett.*, 2004, **4**, 1683-1687.
- 36 S. Bi, J. Zhang and S. Zhang, *Chem. Commun.*, 2010, **46**, 5509-5511.
- 37 N. D. B. Le, M. Yazdani and V. M. Rotello, *Nanomedicine*, 2014, **9**, 1487-1498.
- 38 O. R. Miranda, H.-T. Chen, C.-C. You, D. E. Mortenson, X.-C. Yang, U. H. F. Bunz and V. M. Rotello, *J. Am. Chem. Soc.*, 2010, **132**, 5285-5289.
- 39 O. R. Miranda, X. Li, L. Garcia-Gonzalez, Z.-J. Zhu, B. Yan, U. H. F. Bunz and V. M. Rotello, *J. Am. Chem. Soc.*, 2011, **133**, 9650-9653.
- 40 A. M. Martinez and A. C. Kak, *IEEE Trans. Pattern Anal.*, 2001, **23**, 228-233.
- 41 U. H. F. Bunz and V. M. Rotello, *Angew. Chem. Int. Ed.*, 2010, **49**, 3268-3279.
- 42 A. Bajaj, O. R. Miranda, I.-B. Kim, R. L. Phillips, D. J. Jerry, U. H. F. Bunz and V. M. Rotello, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 10912-10916.
- 43 A. Bajaj, S. Rana, O. R. Miranda, J. C. Yawe, D. J. Jerry, U. H. F. Bunz and V. M. Rotello, *Chem. Sci.*, 2010, **1**, 134-138.
- 44 S. Rana, A. K. Singla, A. Bajaj, S. G. Elci, O. R. Miranda, R. Mout, B. Yan, F. R. Jirik and V. M. Rotello, *ACS Nano*, 2012, **6**, 8233-8240.
- 45 R. L. Phillips, O. R. Miranda, C.-C. You, V. M. Rotello and U. H. F. Bunz, *Angew. Chem. Int. Ed.*, 2008, **47**, 2590-2594.
- 46 Q. Liu, Y.-C. Yeh, S. Rana, Y. Jiang, L. Guo and V. M. Rotello, *Cancer Lett.*, 2013, **334**, 196-201.

- 
- 47 L. Y. Wang, R. X. Yan, Z. Y. Hao, L. Wang, J. H. Zeng, J. Bao, X. Wang, Q. Peng and Y. D. Li, *Angew. Chem. Int. Ed.*, 2005, **44**, 6054-6057.
- 48 Y. Lu, Y. Liu, S. Zhang, S. Wang, S. Zhang and X. Zhang, *Anal. Chem.*, 2013, **85**, 6571-6574.
- 49 S. Rana, N. D. B. Le, R. Mout, K. Saha, G. Y. Tonga, R. E. S. Bain, O. R. Miranda, C. M. Rotello and V. M. Rotello, *Nat. Nanotechnol.*, 2015, **10**, 65-69.